<DOC>
	<DOCNO>NCT02929329</DOCNO>
	<brief_summary>The purpose study determine treatment omecamtiv mecarbil/AMG 423 add standard care well tolerate superior placebo reduce risk cardiovascular death heart failure event subject chronic HFrEF .</brief_summary>
	<brief_title>Registrational Study With Omecamtiv Mecarbil/AMG 423 Treat Chronic Heart Failure With Reduced Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Key Male female , ≥ 18 ≤ 85 year History chronic HF ( define require treatment HF minimum 30 day randomization ) LVEF ≤ 35 % , set acute decompensation NYHA class II IV Managed HF SoC therapies consistent regional clinical practice guideline accord investigator judgment subject 's clinical status Current hospitalization primary reason HF prior HF hospitalization , urgent HF admission emergency department ( ED ) within 1 year prior screen Elevated BNP NTproBNP Key Currently receive treatment another investigational device drug study , &lt; 30 day since end treatment another investigational device drug study ( y ) Receiving mechanical hemodynamic support mechanical ventilation ≤ 7 day prior randomization Receiving IV inotropes IV vasopressor ≤ 3 day prior randomization Receiving IV diuretic IV vasodilator , supplemental oxygen therapy ≤ 12 hour prior randomization Acute coronary syndrome , stroke , transient ischemic attack , major cardiac surgery , percutaneous coronary intervention , valvuloplasty within 3 month prior randomization Severe uncorrected valvular heart disease , hypertrophic obstructive cardiomyopathy , active myocarditis , constrictive pericarditis , clinically significant congenital heart disease Untreated severe ventricular arrhythmia Systolic BP &gt; 140 mmHg &lt; 85 mmHg , diastolic BP &gt; 90 mmHg TBL ≥ 2x ULN ; AST ALT ≥ 3x ULN eGFR &lt; 20 ml/min/1.73m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>